Elagolix
http://dbpedia.org/resource/Elagolix an entity of type: Thing
L'elagolix est un médicament utilisé comme inhibiteur de l'hormone de libération des gonadotrophines hypophysaires, donné par voie orale.
rdf:langString
Elagolix, sold under the brand name Orilissa, is a gonadotropin-releasing hormone antagonist (GnRH antagonist) medication which is used in the treatment of pain associated with endometriosis in women. It is also under development for the treatment of uterine fibroids and heavy menstrual bleeding in women. The medication was under investigation for the treatment of prostate cancer and enlarged prostate in men as well, but development for these conditions was discontinued. Elagolix is taken by mouth once or twice per day. It can be taken for up to 6 to 24 months, depending on the dosage.
rdf:langString
rdf:langString
Elagolix
rdf:langString
Elagolix
xsd:integer
48187627
xsd:integer
1107938052
rdf:langString
CC03
rdf:langString
H01
rdf:langString
Low
xsd:integer
32
xsd:integer
832720
834153
xsd:integer
177453
xsd:integer
1208155
xsd:integer
9425680
rdf:langString
DB11979
<second>
-21600.0
-22680.0
-38880.0
rdf:langString
Feces: 90%
rdf:langString
Urine: <3%
xsd:integer
5
rdf:langString
right
xsd:integer
30
rdf:langString
Elagolix molecule ball.png
rdf:langString
Sodium salt
xsd:integer
4
rdf:langString
D09335
rdf:langString
D09336
rdf:langString
Rx-only
rdf:langString
a618044
rdf:langString
Liver
xsd:integer
3
xsd:integer
5
rdf:langString
Contraindicated
xsd:integer
11250647
rdf:langString
COc1ccccc1F
xsd:integer
1
rdf:langString
HEAUOKZIVMZVQL-VWLOTQADSA-N
rdf:langString
NBI-56418, ABT-620
rdf:langString
Orilissa, Oriahn
xsd:integer
5
5948
xsd:integer
250
rdf:langString
Elagolix, sold under the brand name Orilissa, is a gonadotropin-releasing hormone antagonist (GnRH antagonist) medication which is used in the treatment of pain associated with endometriosis in women. It is also under development for the treatment of uterine fibroids and heavy menstrual bleeding in women. The medication was under investigation for the treatment of prostate cancer and enlarged prostate in men as well, but development for these conditions was discontinued. Elagolix is taken by mouth once or twice per day. It can be taken for up to 6 to 24 months, depending on the dosage. Side effects of elagolix include menopausal-like symptoms such as hot flashes, night sweats, insomnia, amenorrhea, mood changes, anxiety, and decreased bone density, among others. Elagolix is a GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone receptor (GnRHR), the biological target of the hypothalamic hormone gonadotropin-releasing hormone (GnRH). By blocking the GnRHR, it dose-dependently suppresses the gonadal production and hence circulating levels of sex hormones such as estradiol, progesterone, and testosterone. Elagolix is a short-acting GnRH antagonist, and can be used to achieve either partial or more substantial suppression of sex hormone levels. Reduced estrogen levels in the endometrium are responsible for the efficacy of elagolix in the treatment of endometriosis. Elagolix was first described in 2008 and was approved for medical use in July 2018. It has been described as a "second-generation" GnRH modulator due to its non-peptide and small-molecule nature and its oral activity. Unlike GnRH agonists and older GnRH antagonists, which are peptides and first-generation GnRH modulators, elagolix is not a GnRH analogue as it is not structurally related to GnRH. Elagolix was the first second-generation and orally active GnRH modulator to be introduced for medical use. The introduction of elagolix in the United States and Canada was followed by that of relugolix (brand name Relumina), the next second-generation GnRH antagonist, in Japan in January 2019. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
rdf:langString
L'elagolix est un médicament utilisé comme inhibiteur de l'hormone de libération des gonadotrophines hypophysaires, donné par voie orale.
rdf:langString
Elagolix
xsd:integer
8362
rdf:langString
Rx-only
rdf:langString
F5O
rdf:langString
el" a goe' lix
<perCent>
80.0
xsd:nonNegativeInteger
65421
rdf:langString
Orilissa, Oriahn
xsd:string
832720-36-2
xsd:string
834153-87-6
xsd:string
177453
xsd:string
1208155
xsd:string
DB11979
xsd:string
5948VUI423
xsd:string
5B2546MB5Z
xsd:string
D09335
D09336
xsd:string
a618044
xsd:string
11250647
